Valuation : CEL-SCI Corporation

Market Cap 28.67M 24.67M 23.21M 21.2M 39.67M 2.71B 39.77M 274M 106M 1.39B 108M 105M 4.47B P/E 2026 *
-0.53x
P/E 2027 * -0.26x
Enterprise Value 23.12M 19.89M 18.71M 17.1M 31.98M 2.18B 32.07M 221M 85.82M 1.12B 86.8M 84.91M 3.61B EV / Sales 2026 *
-
EV / Sales 2027 * 3.91x
Free-Float
93.16%
Yield 2026 *
-
Yield 2027 * -
1 day+1.24%
1 week+4.49%
Current month+0.62%
1 month+1.24%
3 months+18.98%
6 months-58.63%
Current year-69.01%
1 week 1.56
Extreme 1.565
1.7
1 month 1.34
Extreme 1.34
1.75
Current year 0.89
Extreme 0.89
6.75
1 year 0.89
Extreme 0.89
11.4
3 years 0.89
Extreme 0.89
96.91
5 years 0.89
Extreme 0.89
387.04
10 years 0.89
Extreme 0.89
1,227.42
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Director/Board Member 73 22/06/2015
Chairman 69 08/07/2024
Date Insider Type Main position Quantity % Market Cap. Importance
25/08/26 Buy

Chief Executive Officer

100,000 0.5722%
14/08/26 Free

Chief Financial Officer

225,000 1.2874%
14/08/26 Free

Director

110,000 0.6294%
Change 5-day change 1-year change 3-year change Capi.($)
+1.24%+4.49%-84.46%-95.85% 28.67M
-0.38%-2.64%+42.69%+99.03% 67.98B
-2.48%-0.46%+34.42%+81.89% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
-1.42%-4.28%+31.24%+13.27% 25.74B
-1.11%+0.90%+23.12%-18.50% 20.09B
+1.15%-14.24%+219.82%+381.14% 17.16B
+0.20%-4.68%-6.41%+560.92% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average -0.24%+1.39%+29.55%+155.17% 27.91B
Weighted average by Cap. -0.75%+0.59%+37.03%+141.20%

Financials

2026 *2027 *
Net sales - 5.97M 5.14M 4.83M 4.42M 8.26M 564M 8.28M 57.13M 22.17M 289M 22.43M 21.94M 932M
Net income -25.08M -21.58M -20.31M -18.55M -34.7M -2.37B -34.8M -240M -93.12M -1.22B -94.19M -92.14M -3.91B -29.51M -25.4M -23.89M -21.83M -40.83M -2.79B -40.94M -282M -110M -1.43B -111M -108M -4.61B
Net Debt -5.55M -4.78M -4.5M -4.11M -7.68M -524M -7.71M -53.13M -20.62M -269M -20.86M -20.4M -867M -5.34M -4.59M -4.32M -3.95M -7.39M -504M -7.41M -51.08M -19.82M -259M -20.05M -19.61M -833M
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
44
Date Price Change Volume
04/09/26 $1.630 +1.24% 75,071
03/09/26 $1.610 -2.42% 117,061
02/09/26 $1.650 +2.48% 134,713
01/09/26 $1.610 -0.62% 70,256
31/08/26 $1.620 +3.85% 56,390
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.630USD
Average target price
12.50USD
Spread / Average Target
+666.87%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!